 Achilles Therapeutics plc NASDAQ: ACHL announced the pricing of its IPO on the Nasdaq that will raise US175.5mln 127.8mln. The clinical-stage biopharma, which is developing precision T cell therapies to treat solid tumours, will place 9.7mln American depositary shares ADSs at US18 a pop. 